直接肾素抑制剂阿利吉仑基础和临床研究进展
被引量:1
摘要
肾素(renin)是肾素一血管紧张素-醛固酮系统(RAAS)起始和限速的蛋白酶,其作用是切断血管紧张素原第10位亮氨酸与第11位缬氨酸之间的肽键,裂介为10肽血管紧张素Ⅰ(AngⅠ),AngⅠ在血管紧张素转换酶(ACE)作用下,再转化为血管紧张素Ⅱ(AngⅡ)。
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2010年第5期478-480,共3页
Chinese Journal of Cardiology
参考文献12
-
1Nguyen G,Delarue F,Burckle C,et al.Pivotal role of the reran/ prorenin receptor in angiotensin Ⅱ production and cellular responses to rennin.J Clin Invest,2002,109:1417-1427.
-
2Menard J,Cuyene T,Peyrard S,et al.Conformational changes in prorenin during renin inhibition in vitro and in vivo.J Hypertens,2006,24:529-534.
-
3Brown MJ.Aliskiren.Circulation,2008,118:773-784.
-
4Wood JM,Maibaum J,Rahuel J,et al.Structure-based design of aliskiren,a novel orally effective renin inhibitor.Biochem Biophys Res Commun,2003,308:698-705.
-
5Batenburg WW,de Bruin RJ,van Gool JM,et al.Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.Arterioscler Thromb Vase Biol,2008,26(Suppll):S199.
-
6Frampton.JE,Curran MP.Aliskiren,a review of its use in the management of hypertension.Drugs,2007,67:1767-1792.
-
7Gradman AH,Schmieder RE,Lins RL,et al.Aliskiren,a novel orally effective renin inhibitor,provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.Circulation,2005,111:1012-1018.
-
8Oh BH,Mitchell J,Herron JR.et al.Aliskiren,an oral renin inhibitor,provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.J Am Coll Cardiol,2007,49:1157-1163.
-
9Oparil S,Yarows SA,Patel S,et al.Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension:randomised double-blind trial.Lancet,2007,370:221-229.
-
10Lambers Heerspink HJ,Perkovic V,de Zeeuw D.Renal and cardio-protective effects of direct renin inhibition:a systematic literature review.J Hypertens,2009,27:2321-2331.
同被引文献30
-
1Dzau V. The cardiovascular continuum and renin-angiotensin- aldosterone system blockade. J Hypertens Suppl, 2005,23: S9-17.
-
2Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases : do we need a more comprehensive strategy? Rev Cardiovasc Med, 2006,7: 45-54.
-
3Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Phannacol, 2009,78 : 933-940.
-
4Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag, 2010, 6: 869-882.
-
5Masson S, Solomon S, Angelici L, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail, 2010, 16: 964- 970.
-
6Kappert K, Unger T, Kintscher U. Aliskiren hemifumarate. Dtsch Med Wochenschr, 2008,133 : 1308-1312.
-
7Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coil Cardiol, 2007, 49 : 1157-1163.
-
8Batenburg WW, de Bruin 1LI, van Gool JM, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2008, 28: 1151-1157.
-
9Epstein BJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag, 2010, 6 : 711-722.
-
10Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension : a 6-month, randomized, double-blind trial. J Hypertens, 2008, 26: 589-599.
-
1黄震华,徐济民.抗高血压新药肾素抑制剂[J].中国新药与临床杂志,1998,17(3):171-172. 被引量:7
-
2郑敏,刘必成.肾素抑制剂研究新进展[J].中华高血压杂志,2008,16(4):297-299. 被引量:1
-
3申晨,龚开政,张振刚.新型降压药——直接肾素抑制剂阿利吉仑的降压及靶器官保护效应[J].心血管病学进展,2013,34(5):675-678. 被引量:7
-
4鲁向楠.ACEI与ARB的效果一样吗?[J].心血管病防治知识,2010(2):32-32.
-
5严山,张学锋,田晓沂,李江津,庄凌,姜宜成,徐琢.人类肾素血管紧张素系统分子遗传学研究进展[J].中华生物医学工程杂志,2013,19(2):168-171. 被引量:1
-
6袁勇.血管紧张素Ⅱ的受体和拮抗剂研究进展[J].岭南心血管病杂志,1998,4(1):60-61. 被引量:4
-
7王飞宇,白元,蔡亚梅,秦永文.直接肾素抑制剂阿利吉仑治疗高血压病的研究进展[J].药学服务与研究,2014,14(2):118-121. 被引量:3
-
8张岩,李晓莉,顾洒洒.维生素D联用RAS抑制剂的药理作用研究进展[J].中国药师,2011,14(2):189-191. 被引量:2
-
9王翠玉,赵永英,高秀莲,王依新.直接肾素抑制剂阿利吉仑临床研究进展[J].中国当代医药,2011,18(31):8-9. 被引量:1
-
10曾庆春,许顶立.直接肾素抑制剂的心血管保护作用[J].中华心血管病杂志,2010,38(7):668-669. 被引量:2